Search

ADH-1

ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors. … As many tumors become more aggressive, invasive, and malignant, researchers have found that N-cadherin is expressed in greater amounts, making it an important target for developing anti-cancer treatments

EGS21

GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders.

CERE-110

This drug is developed by Ceregene and currently under phase I of clinical trial. … CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

AZD 3355

AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

Regramostim

GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.

TBC-3711

TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

Flurithromycin

Cefozopran

Terodiline

Perflubron

Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.